RESEARCH TRIANGLE PARK, N.C., March 11, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today announced the initiation of a Phase II proof-of-concept study of senicapoc, a novel orally available small molecule inhibitor of the KCa3.1 potassium ion channel, in patients with exercise-induced asthma. This study complements an ongoing proof-of-concept study in patients with allergic asthma which the Company initiated during the fourth quarter of 2008.
